Cargando…

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy

If the world can successfully control all outbreaks of circulating vaccine-derived poliovirus that may occur soon after global oral poliovirus vaccine (OPV) cessation, then immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) from rare and mostly asymptomatic long-term excretors (define...

Descripción completa

Detalles Bibliográficos
Autores principales:	DUINTJER TEBBENS, R. J., THOMPSON, K. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2017
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5197684/ https://www.ncbi.nlm.nih.gov/pubmed/27760579 http://dx.doi.org/10.1017/S0950268816002302

Ejemplares similares

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2017)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes
por: Thompson, Kimberly M., et al.
Publicado: (2015)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2017)

How should we prepare for an outbreak of reintroduced live polioviruses?
por: Thompson, Kimberly M, et al.
Publicado: (2017)

Protocol Paper: Oral Poliovirus Vaccine Transmissibility in Communities After Cessation of Routine Oral Poliovirus Vaccine Immunization
por: Sarnquist, Clea, et al.
Publicado: (2018)

Another look at silent circulation of poliovirus in small populations
por: Kalkowska, Dominika A., et al.
Publicado: (2018)

An economic analysis of poliovirus risk management policy options for 2013–2052
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2015)

Global oral poliovirus vaccine stockpile management as an essential preparedness and response mechanism for type 2 poliovirus outbreaks following global oral poliovirus vaccine type 2 withdrawal()
por: Harutyunyan, Vachagan, et al.
Publicado: (2023)

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination
por: Kalkowska, Dominika A, et al.
Publicado: (2015)

Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV)
por: Thompson, Kimberly M., et al.
Publicado: (2019)

Vaccine-Derived Polioviruses and Children with Primary Immunodeficiency, Iran, 1995–2014
por: Shaghaghi, Mohammadreza, et al.
Publicado: (2016)

Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine
por: Zhao, Ting, et al.
Publicado: (2021)

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission
por: Duintjer Tebbens, Radboud J, et al.
Publicado: (2019)

Randomized Controlled Clinical Trial of Bivalent Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine in Nigerian Children
por: Tagbo, Beckie N, et al.
Publicado: (2020)

Recombinant Vaccine–Derived Poliovirus in Madagascar
por: Rousset, Dominique, et al.
Publicado: (2003)

Vaccine–derived Poliovirus, Thailand, 2003
por: Tharmaphornpilas, Piyanit
Publicado: (2005)

Outbreak response strategies with type 2-containing oral poliovirus vaccines ()
por: Kalkowska, Dominika A., et al.
Publicado: (2023)

Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation
por: Thompson, Kimberly M., et al.
Publicado: (2023)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Asymptomatic immunodeficiency-associated vaccine-derived poliovirus infections in two UK children
por: Singanayagam, Anika, et al.
Publicado: (2023)

Environmental Surveillance of Polioviruses in Armenia, Colombia before Trivalent Oral Polio Vaccine Cessation
por: González, María Mercedes, et al.
Publicado: (2019)

Does Simultaneous Administration of Bivalent (Types 1 and 3) Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Induce Mucosal Cross-immunity to Poliovirus Type 2?
por: Resik, Sonia, et al.
Publicado: (2018)

Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines
por: Alipon, SweetC B, et al.
Publicado: (2022)

Vaccine-Derived Polioviruses Not Detected by Global Surveillance Screening Assay
por: Sharma, Deepa K., et al.
Publicado: (2015)

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication
por: Galal, Nermeen M., et al.
Publicado: (2018)

Decay of Sabin inactivated poliovirus vaccine (IPV)-boosted poliovirus antibodies
por: Resik, Sonia, et al.
Publicado: (2015)

The effect of maternal poliovirus antibodies on the immune responses of infants to poliovirus vaccines
por: Jia, Siyue, et al.
Publicado: (2020)

Assessment of poliovirus antibody seroprevalence in high risk areas for vaccine derived poliovirus transmission in Madagascar
por: Razafindratsimandresy, Richter, et al.
Publicado: (2018)

Estimating the Extent of Vaccine-Derived Poliovirus Infection
por: Wringe, Alison, et al.
Publicado: (2008)

The Case for Live Poliovirus Vaccination
por: Paul, John R.
Publicado: (1960)

Fecal Shedding of 2 Novel Live Attenuated Oral Poliovirus Type 2 Vaccine Candidates by Healthy Infants Administered Bivalent Oral Poliovirus Vaccine/Inactivated Poliovirus Vaccine: 2 Randomized Clinical Trials( )
por: Gast, Christopher, et al.
Publicado: (2021)

Immunodeficiency-associated Vaccine-Derived Poliovirus Type 3 in Infant, South Africa, 2011
por: Gumede, Nicksy, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6albj4g8lj7cdpcr1bea7dmpjn